Track topics on Twitter Track topics that are important to you
Elliot Norry, acting chief medical officer of Adaptimmune (NASDAQ: ADAP) since last August, now holds the job outright. Norry initially joined the company in 2015 as head of clinical safety and pharmacovigilance. Adaptimmune, which splits its operations between Philadelphia and Oxfordshire, UK, is developing cancer immunotherapies based on its technology for engineering T cells.
Original Article: Adaptimmune Appoints Elliot Norry Chief Medical OfficerNEXT ARTICLE
Clinical Research Organization
Contract Research Organization (CRO) provide research services outsourced on a contract basis to the pharmaceutical, biotechnology, healthcare and medical device industries: biopharmaceutical development biologic assay development commercial...
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...